Skip to main content

Table 5 Adjusted ORs for uptake of AS in relation to previous number of PSA tests and any prior negative biopsy, stratified by 1) risk and 2) period of diagnosis (History for the 5-year period before diagnosis)

From: Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?

Stratified by:

Number of PSA tests

Number of biopsies

OR

95% CI

p-value

OR

95% CI

p-value 

Risk category

 Very low risk (n = 1568)

0.99

0.96–1.04

0.681

1.06

0.78–1.38

0.702

 Low risk (n = 2292)

0.99

0.96–1.03

0.984

1.14

0.94–1.38

0.187

Year of diagnosis

 2008–2010 (n = 1,339)

0.98

0.94–1.03

0.485

1.21

0.95–1.56

0.121

 2011–2012 (n = 818)

1.02

0.98–1.07

0.366

0.93

0.71–1.21

0.594

 2013–2014 (n = 1703)

0.99

0.93–1.05

0.791

1.00

0.73–1.37

0.995

  1. CI confidence interval, OR odds ratio, PSA prostate specific antigen
  2. ORs derived from separate multivariable logistic regression models adjusted for age, education level, civil status, CCI, family history, symptoms, diagnosis year and risk category (simultaneous adjustment for no. PSA tests and biopsy)
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us